Proteomic and phosphoproteomic profiling identifies plasma small-vesicle pFLNA-Ser1459 as a candidate marker across healthy controls, high-risk adenoma and colorectal cancer. Independent blinded validation and an analytically standardised assay are required before screening use.
Key findings
- Proteomic and phosphoproteomic profiling identifies plasma small-vesicle pFLNA-Ser1459 as a candidate marker across healthy controls, high-risk adenoma and colorectal cancer. Independent blinded validation and an analytically standardised assay are required before screening use.
Why this matters globally
This work adds internationally comparable evidence in Health sciences and defines questions for replication in other populations or systems. Its global value lies in the evidence and transferable reasoning, not in a single impact score.
Thai researcher contribution
Thailand-linked authors and Prince of Songkla University, Chulabhorn Research Institute, Chulabhorn Hospital, Siriraj Hospital, Mahidol University contribute to the research network behind this work. Thai participation is identified from bibliographic affiliations and should be checked against the author list and source article.
Limitations to consider
Controlled experiments do not establish in-vivo safety, clinical effectiveness, durability or industrial economics.